Neuropeptides

American Journal of Rhinology

Volumn 12, Issue 1, 1998, Pages 9-16

  Baraniuk, James N ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE METALLOENDOPEPTIDASE; NEUROPEPTIDE;

ADRENERGIC SYSTEM; CHOLINERGIC SYSTEM; COUGHING; HUMAN; INNERVATION; NEUROLOGIC DISEASE; NOCICEPTIVE RECEPTOR; NOSE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SENSORY NERVE CELL;

COUGH; HUMANS; NEPRILYSIN; NERVOUS SYSTEM DISEASES; NEURONS, AFFERENT; NEUROPEPTIDES; NOCICEPTORS; NOSE; PARASYMPATHETIC NERVOUS SYSTEM; SYMPATHETIC NERVOUS SYSTEM;

EID: 0031606149     PISSN: 10506586     EISSN: None     Source Type: Journal    
DOI: 10.2500/105065898782103025     Document Type: Article

References (66)

1. Lundblad L. Protective reflexes and vascular effects in the nasal mucosa elicited by activation of capsaicin-sensitive substance P-immunoreactive trigeminal neurons. Acta Physiol Scand Suppl 529:1-42, 1984.
2. Hua XY. Tachykinins and calcitonin gene related peptide in relation to peripheral functions of capsaicin-sensitive sensory nerves. Acta Physiol Scand 127 Suppl 551:1-45, 1986.
3. Uddman R, Sundler F. Innervation of the upper airways. Clin Chest Med 7:201-209, 1986.
4. Barnes PJ, Baraniuk JN, Belvisi MG. Neuropeptides in the respiratory tract. Part 1. Am Rev Respir Dis 144:1187-1198, 1991.
5. Barnes PJ, Baraniuk JN, Belvisi, MG. Neuropeptides in the respiratory tract. Part 2. Am Rev Respir Dis 144:1391-1399, 1991.
6. Baraniuk JN. Neural control of human nasal secretion. Pulm Pharmacol 4: 20-31, 1991.
7. Raphael GR, Baraniuk JN, Kaliner MA. How and why the nose runs.J Allergy Clin Immunol 87:457-467, 1991.
8. Cauna N. Blood and nerve supply of the nasal lining. In The Nose: Upper Airway Physiology and the Atmospheric Environment. Ch. 3 Proctor DF, Anderson I (Eds) Amsterdam: Elsevier Biomedical Press BV, 45-69, 1992.
9. Lundberg JM. Pharmacology of cotransmission in the autonomic nervous system: Integrative aspects on amines, neuropeptides, adenosine triphosphate, amino acids, and nitric oxide. Pharmacol Rev 48:113-178, 1996.
10. Dray A, Urban L, Dickenson A. Pharmacology of chronic pain. TIPS 15:190-197, 1994.
11. Demski LS, Schwanzel-Fukuda M, Eds. The terminal nerve (nervus terminalis). Ann N Y Acad Sci 519:1-213, 1987.
12. Barr ML. The human nervous system. 2nd ed. Hagerstown, MD: Harper & Row, 1974.
13. Chen Z, Hedner J, Hedner T. Local effects of substance P on respiratory regulation in the rat medulla oblongata. J Appl Physiol 68:693-699, 1990.
14. Baraniuk JN, Lundgren JD, Goff J, et al. Bradykinin receptor distribution in human nasal mucosa, and analysis of in vitro secretory responses in vitro and in vivo. Am Rev Respir Dis 141:706-714, 1990.
15. Martins MA, Shore SA, Drazen JM. Release of tachykinins by histamine, methacholine, PAF, LTD4, and substance P from guinea pig lungs. Am J Physiol 261 (Lung Cell:Mol Physiol.5): L449-L455, 1991.
16. Raphael GD, Igarashi Y, White MV, Kaliner MA. The pathophysiology of rhinitis. V. Sources of protein in allergen-induced nasal secretions. J Allergy Clin Immunol 88:33-43, 1991.
17. Baraniuk JN, Lundgren JD, Goff J, et al. Calcitonin gene related peptide (CGRP) in human nasal mucosa. Am J Physiol 258:L81-L88, 1990.
18. Baraniuk JN, Lundgren JD, Goff J, et al. Gastrin releasing peptide (GRP) in human nasal mucosa. J Clin Invest 85:998-1005, 1990.
19. Holzer P. Local effector functions of capsaicin-sensitive sensory nerve endings: Involvement of tachykinins, calcitonin gene related peptide, and other neuropeptides. Neuroscience 24:739-768, 1988.
20. McDonald DM. Neurogenic inflammation in the rat trachea. I. Changes in venules, leukocytes, and epithelial cells. J Neurocytol 17:605-628, 1988.
21. Baraniuk JN, Lundgren JD, Okayama M, et al. Substance P and neurokinin A (NKA) in human nasal mucosa. Am J Respir Cell Mol Biol 4:228-236, 1991.
22. Carstairs JR, Barnes PJ. Autoradiographic mapping of substance P receptors in lung. Eur J Pharamacol 127:295-296, 1988.
23. Nadel JA. Decreased neutral endopeptidases: Possible role in inflammatory diseases of airways. Lung 123(Suppl):123-127, 1990.
24. Nadel JA. Membrane-bound peptidases: Endocrine, paracrine, and autocrine effects. Am J Respir Cell Mol Biol 7:469-470, 1992.
25. Borson DB. Roles of neutral endopeptidase in airways. Am J Physiol 260(Lung Cell:Mol Physiol 4):L212-L225, 1991.
26. Noble F, Dauge V, Fournie-Zaluski MC, Beaumont A. Neutral endopeptidase 24.11: Structure, inhibition, and experimental and clinical pharmacology. Pharmacolog Rev 45:87-146, 1993.
27. Baraniuk JN, Okayama M, Lundgren JD, et al. Vasoactive intestinal peptide (Vi.p.) in human nasal mucosa. J Clin Invest 86:825-831, 1990.
28. Kobzik L, Bredt DS, Lowenstein CJ, et al. Nitric oxide synthetase in human and rat lung: Immunocytochemical and histochemical localization. Am J Respir Cell Mol Biol 9:371-377, 1993.
29. Watson N, Maclagan J, Barnes PJ. Vagal control of guinea pig tracheal smooth muscle: Lack of involvement of Vi.p. or nitric oxide. J Appl Physiol 74:1964-1971, 1993.
30. Fisher JT, Anderson JW, Waldron MA. Nonadrenergic noncholinergic neurotransmitter of feline trachealis: Vi.p. or nitric oxide? J Appl Physiol 74:31-39, 1993.
31. Barnes PJ. Muscarinic receptor subtypes: Implications for lung disease. Thorax 44:161-167, 1989.
32. Levine RR, Birdsall NJM, North RA, et al. Subtypes of muscarinic receptors III. Trends Pharmacol Sci 9(Suppl):1-93, 1991.
33. Mak JCW, Barnes PJ. Autoradiographic visualization of muscarinic receptor subtypes in human and guinea pig lung. Am Rev Respir Dis 141:1559-1568, 1990.
34. Dorje F, Wess J, Lambrecht G, et al. Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J Pharmacol Exp Ther 256:727-733, 1991.
35. Okayama M, Baraniuk JN, Merida M, Kaliner MA. Autoradiographic localization of muscarinic receptor subtypes in human nasal mucosa. Am J Respir Cell Mol Biol 8:176-185, 1993.
36. Richerson HB, Seebohm PB. Nasal airway response to exercise. J Allergy 41:269-284, 1968.
37. Baraniuk JN, Castellino S, Goff J, et al. (1990a) Neuropeptide Y (NPY) in human nasal mucosa. Am. J. Respir. Cell. Mol. Biol. 3,165-173,1990.
38. Lacroix JS, Anggard A, Hokfelt T, et al. Neuropeptide Y: Presence in sympathetic and parasympathetic innervation of the nasal mucosa. Cell Tissue Res 259:119-128, 1990.
39. Lacroix JC, Mosimman BL. Attenuation of allergen-evoked nasal responses by local pretreatment with exogenous neuropeptide Y in atopic patients. J Allergy Clin Immunol 98:611-616, 1996.
40. Barnes PJ. Modulation of neurotransmission in airways. Physiol Rev 72:699, 1992.
41. Mullol J, Baraniuk JN, Logun C, et al. M1 and M3 muscarinic antagonists inhibit human nasal glandular secretion in vitro. J Appl Physiol 73:2069-2073, 1992.
42. Mak JCW, Baraniuk JN, Barnes PJ. Localization of muscarinic receptor subtype mRNAs in human lung. Am J Respir Cell Mol Biol 7:344-348, 1992.
43. Smith, CH, Barker, JNWN, Morris, RW, et al. Neuropeptides induce rapid expression of endothelial cell adhesion molecules and elicit granulocytic infiltration in human skin. J Immunol 151:3274-3282, 1993.
44. Mossiman, BL, White, MV, Hohman, RJ, et al. Substance P, calcitonin-gene related peptide, and vasoactive intestinal peptide increase in nasal secretions after allergen challenge in atopic patients. J Allergy Clin Immunol 92:95-104, 1993.
45. Tomaki M, Ichinose M, Miura M, et al. Elevated substance P content in induced sputum from patients with asthma and patients with chronic bronchitis. Am J Respir Crit Care Med 151:613-617, 1995.
46. Bai TR, Zhou D, Weir T, et al. Substance P (NK1)-, and Neurokinin A (NK2)-receptor expression in inflammatory airway disease. Am J Physiol 269(Lung Cell Mol Physiol 13): L309-L317, 1995.
47. Okayama Y, Shirotori K, Kudo K, et al. Cytokine expression after the topical administration of substance P to human nasal mucosa. J Immunol 151:4391-4398, 1993.
48. Baraniuk JN, Silver PB, Kaliner MA, Barnes PJ. Perennial rhinitis subjects have altered vascular, glandular, and neural responses to bradykinin nasal provocation. Int Arch Allergy Immunol 103:202-208, 1994.
49. Ricchio MM, Reynolds CJ, Hay DW, Proud D. Effects of intranasal administration of endothelin-1 to allergic and nonallergic individuals. Am J Respir Crit Care Med 152:1757-1764, 1995.
50. Ricchio MM, Proud D. Evidence that enhanced neural reactivity to bradykinin in patients with symptomatic allergy is mediated by neural reflexes. J Allergy Clin Immunol 97:1252-1253, 1996.
51. Druce HM, Wright RH, Kossoff D, Kaliner MA. Cholinergic nasal hyperreactivity in atopic subjects. J Allergy Clin Immunol 76:445-452, 1985.
52. Stjarne P, Lundblad L, Lundberg JM, Anggard A. Capsaicin and nicotine sensitive afferent neurones and nasal secretion in healthy human volunteers and in patients with vasomotor rhinitis. Br J Pharmacol 96:693-701, 1989.
53. Mygind N, Naclerio RM, editors. Allergic, and Nonallergic Rhinitis: Clinical Aspects. 2d ed. Munksgaard, Philadephia, PA, 1993.
54. Raphael G D, Haupstein-Raphael M, Kaliner MA. Gustatory rhinitis: a syndrome of food-induced rhinorrhea. J Allergy Clin Immunol 83:110-115, 1989.
55. Stjarne P, Lacroix JS, Anggard A, Lundberg JM. Compartment analysis of vascular effects of neuropeptides and capsaicin in the pig nasal mucosa. Acta Physiol Scand 141:335-342, 1991.
56. Willes S, Fitzgerald T, Bascom R. Nasal inhalation challenge studies with sidestream tobacco smoke. Arch Environ Health 47:223-230, 1992.
57. Stone RA, Fuller RW. Mechanisms of cough. In Asthma and Rhinitis, Busse WW, Holgate ST (Eds) Blackwell, Oxford, 1995, 1075-1083.
58. O'Connell F, Springall DR, Moradoghli-Haftvani A, Krausz, Price D, Fuller RW, Polak JM, Pride NB. Abnormal intraepithelial airway nerves in persistent unexplained cough? Am J Respir Crit Care Med 152:2068-2075, 1995.
59. Bucca C, Rolla G, Scappaticci E, Chiamp F, Bugiani M, Magnano M, D'Alberto M. Extrathoracic and intrathoracic airway responsiveness in sinusitis. J Allergy Clin Immunol 95:52-59, 1995.
60. Anderson SA, Togias AG. Dry air and hyperosmolar challenge in asthma and rhinitis. In Asthma and Rhinitis, Busse WW, Holgate ST (Eds) Marcel Dekker, New York, 1995, 1178-1195.
61. Taddese A, Nah SY, McCleskey EW. Selective opioid inhibition of small nociceptive neurons. Science 270:1366-1369, 1995.
62. Bolser DC, O'Reilly S, DeGennaro FC, Hey JA. Antitussive activity of NK1 and NK2 antagonists in the guinea pig and cat. Am J Respir Crit Care Med 151:A816, 1995.
63. Baraniuk JN, Ohkubo K, Kwon OJ, et al. Localization of neutral endopeptidase (NEP) mRNA in human bronchi. Eur Respir J 8:1458-1464, 1995.
64. Lurie A, Nadel JA, Roisman G, et al. Role of neutral endopeptidase and kininase II on substance P-induced increase in nasal obstruction in patients with allergic rhinitis. Am J Respir Crit Car Med 149:113-117, 1994.
65. Cheung D, Bel EH, den Hartigh J, et al. The effect of inhaled neutral endopeptidase inhibitor, thiorphan, on airway responses to neurokinin A in normal humans in vivo. Am Rev Respir Dis 145:1275-1280, 1992.
66. Crimi N, Palermo F, Oliveri R, et al. Effect of nedocromil on bronchospasm induced by inhalation of substance P in asthmatic subjects. Clinical Allergy 18:375-382, 1988.